metastatic castration-resistant prostate cancer

December 1, 2020December 1, 2020

FDA Approves FoundationOne Liquid CDx as Companion Test for Lynparza in mCRPC Patients

News

The U.S. Food and Drug Administration (FDA) has approved FoundationOne Liquid CDx to be used as a companion diagnostic test to identify men with metastatic castration-resistant prostate cancer (mCRPC) who ... Read more

November 10, 2020November 10, 2020

European Commission OKs Lynparza for Metastatic CRPC With BRCA Mutations

News

The European Commission has approved Lynparza (olaparib) to treat people with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in the DNA repair genes BRCA1 and BRCA2. The approval follows a positive ... Read more

November 5, 2020November 5, 2020

Hold Lifted on Phase 1 Trial Testing P-PSMA-101 CAR T-cell Therapy in mCRPC

News

A Phase 1 trial evaluating Poseida Therapeutics’ autologous CAR T-cell therapy P-PSMA-101 for metastatic castration-resistant prostate cancer (mCRPC) is resuming immediately, after its clinical hold was lifted. The U.S. Food ... Read more

October 8, 2020October 8, 2020

Veru Completes Enrollment for Second Part of Phase 1/2 VERU-111 Trial

News

Veru has completed enrollment for the second portion of a Phase 1/2 study of VERU-111, its investigational therapy for men with metastatic castration-resistant prostate cancer (mCRPC) who failed to respond ... Read more

August 31, 2020August 31, 2020

FDA Approves Blood Test That Can Identify Cancers Eligible for Targeted Therapies

News

The U.S. Food and Drug Administration (FDA) has approved FoundationOne Liquid CDx, a blood test that can be used to identify cancer patients who may benefit from certain targeted therapies, including ... Read more

May 22, 2020May 22, 2020

Rubraca Receives Conditional FDA Approval for metastatic CRPC Patients with BRCA Mutations

News

The U.S. Food and Drug Administration (FDA) has granted conditional approval to Rubraca (rucaparib) for treating patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations who have previously received ... Read more

May 21, 2020May 22, 2020

FDA Approves Lynparza for mCRPC Patients with Mutations in DNA Repair Genes

News

The U.S. Food and Drug Administration has approved the oral therapy Lynparza (olaparib) for treating men with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in homologous recombination repair (HRR) genes, including ... Read more

May 8, 2020May 8, 2020

Yervoy Can Benefit Certain mCRPC Patients with Few Mutations in Tumors, Trial Finds

News

Men with metastatic castration-resistant prostate cancer (mCRPC) showing evidence of active immune responses in their tumors live longer without disease progression after being treated with Yervoy (ipilimumab), a Phase 2 ... Read more

April 17, 2020April 17, 2020

Cancer Vaccine Plus Opdivo Showing Promise in Advanced Prostate Cancer Trial

News

A combination of Vaccitech’s experimental vaccine VTP-800 and Opdivo (nivolumab) appears to be a safe and potentially effective treatment for men with metastatic castration resistant prostate cancer (mCRPC), according to early data from ... Read more

February 24, 2020February 24, 2020

Cabometyx-Tecentriq Combo Leads to Lasting Response in Men with Advanced PC, Phase 1b Trial Data Shows

News

The combination of Cabometyx (cabozantinib) and Tecentriq (atezolizumab) is safe and shows clinically meaningful activity, leading to lasting responses in men with metastatic castration-resistant prostate cancer (mCRPC), a Phase 1b trial ... Read more